Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis - Full Text View

Purpose

The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis

Condition	Intervention	Phase
Allergic Conjunctivitis	Drug: Lifitegrast Other: Placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model

Resource links provided by NLM:

MedlinePlus related topics: Pinkeye

Drug Information available for: Lifitegrast

U.S. FDA Resources

Further study details as provided by Shire:

Primary Outcome Measures:

Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6]) [ Time Frame: Baseline to Day 7 (7 minutes post CAC 6) ]
Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching. CAC is an initial titration challenge to determine the appropriate allergen and lowest concentration of allergen that produced a positive bilateral allergic response for each subject, defined as ≥ 2 score (0-4 point scale) in ocular itching and conjunctival redness within 10 minutes of the last titration of allergen.
Ocular Itching at Day 14 (7 Minutes Post CAC 9) [ Time Frame: Baseline to Day 14 (7 minutes post CAC 9) ]
Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.
Conjunctival Redness at Day 7 (20 Minutes Post CAC 6) [ Time Frame: Baseline to Day 7 (20 minutes post CAC 6) ]
Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.
Conjunctival Redness at Day 14 (20 Minutes Post CAC 9) [ Time Frame: Baseline to Day 14 (20 minutes post CAC 9) ]
Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

Secondary Outcome Measures:

Ocular Itching at Day 6 (CAC 4), 5 (CAC 7) [ Time Frame: Baseline to Day 6 (CAC 4), Day 13 (CAC 7) 7 minutes post CAC ]
Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.
Conjunctival Redness at Day 6 (CAC 4), 5 (CAC 7) [ Time Frame: Baseline to Day 6 (CAC 4), Day 13 (CAC 7) at 20 minutes post CAC ]
Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.


Enrollment:	60
Study Start Date:	April 2009
Study Completion Date:	May 2009
Primary Completion Date:	May 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 0.1% Lifitegrast	Drug: Lifitegrast Ophthalmic Solution Other Name: SAR 1118
Experimental: 1.0% Lifitegrast	Drug: Lifitegrast Ophthalmic Solution Other Name: SAR 1118
Experimental: 5.0% Lifitegrast	Drug: Lifitegrast Ophthalmic Solution Other Name: SAR 1118
Placebo Comparator: Placebo	Other: Placebo Ophthalmic Solution

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed informed consent form and HIPAA document
Willing and able to comply with all study procedures
Be at least 18 years of age at the time of enrollment
20/40 vision, or better, in each eye
History of ocular allergies, and a positive skin and ocular allergic reaction to allergens
A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period

Exclusion Criteria:

Preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, glaucoma, diabetic retinopathy, clinically significant blepharitis, follicular conjunctivitis and iritis)
Have had any ocular infection within the last 30 days
A positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears)
Any significant illness that could be expected to interfere with study parameters
Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye
Use of any investigational product or device within one month prior to Visit 1 or during the study period
Concomitant use of any prohibited medication (antihistamines, corticosteroids, all ocular medications or anti-allergic therapies) during the trial or within the washout period
Any blood donation or significant loss of blood within 56 days of Visit 1
Any history of autoimmune disease, immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti‑HAV IgM), or organ or bone marrow transplant. Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis
History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 3 months prior to Visit 1
Known history of alcohol abuse and/or drug abuse

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00882687

Locations


United States, Massachusetts
Ora
Andover, Massachusetts, United States, 01810

Sponsors and Collaborators

Shire

Investigators


Principal Investigator:	Gail Torkildsen, MD	ORA, Inc.

More Information


Responsible Party:	Shire
ClinicalTrials.gov Identifier:	NCT00882687 History of Changes
Other Study ID Numbers:	1118-ACJ-100
Study First Received:	April 15, 2009
Results First Received:	November 6, 2015
Last Updated:	January 5, 2017

Additional relevant MeSH terms:


Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate	Hypersensitivity Immune System Diseases Ophthalmic Solutions Pharmaceutical Solutions

ClinicalTrials.gov processed this record on June 27, 2017